You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
高盛:股價迎多重利好 維持華領醫藥(2552.HK)買入評級及目標價12.7港元
格隆匯 08-20 10:56
格隆匯8月20日丨高盛8月19日發研報指,華領醫藥(2552.HK)公佈2021年中期業績,報吿期內,公司開支總額約為1.65億元;行政開支大致持平,為6400萬元(同比下降4%);因三期臨牀試驗完成,研發開支温和下降,約為9800萬元(同比下降13%)。華領醫藥提交的dorzagliatin的NDA申請已於4月獲得NMPA受理,有望在1H22獲批。此外,華領醫藥計劃在上海建立一個製造工廠,以支持潛在的產品上市和潛在的納入NRDL(國家醫保藥品目錄)後的放量。高盛認為,近期催化劑是將於9月25日至27日CBII conference上由研究者發起的DREAM研究的數據展示。該研究旨在評估經過dorzagliatin單藥治療後,停止用藥後患者的血糖控制情況和β細胞功能。其他催化劑包括NDA預計於1H22的潛在獲批及潛在的全球合作。高盛將2021-23年的預測淨虧損分別調整-28%/+3%/+5%,以反映由於III期臨牀試驗完成導致的2021年研發支出的下降,維持“買入”評級和目標價12.7港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account